Gabriel Plotkin Ligand Pharmaceuticals Inc Put Options Transaction History

Melvin Capital Management LP

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2020 Apr 28, 2021	BUY	$80.55 - $106.05 $72.5 Million - $95.4 Million	900,000 New	900,000 $89.5 Million
Q4 2020 Feb 16, 2021	SELL	$80.55 - $106.05 $48.3 Million - $63.6 Million	-600,000 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$89.56 - $126.72 $17.9 Million - $25.3 Million	200,000 Added 50.0%	600,000 $57.2 Million
Q2 2020 Aug 14, 2020	SELL	$68.28 - $123.65 $11.5 Million - $20.8 Million	-168,500 Reduced 29.64%	400,000 $44.7 Million
Q1 2020 May 15, 2020	BUY	$63.37 - $107.88 $17 Million - $29 Million	268,500 Added 89.5%	568,500 $41.3 Million
Q4 2019 Feb 14, 2020	SELL	$96.94 - $113.59 $19.4 Million - $22.7 Million	-200,000 Reduced 40.0%	300,000 $31.3 Million
Q3 2019 Nov 14, 2019	BUY	$86.25 - $120.16 $43.1 Million - $60.1 Million	500,000 New	500,000 $49.8 Million

277

18.5M

30.8K

5.2K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $1.83B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of Melvin Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Melvin Capital Management LP and Gabriel Plotkin with notifications on news.